# A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI

> **NCT06155110** · PHASE4 · COMPLETED · sponsor: **Chinese PLA General Hospital** · enrollment: 160 (actual)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DRUG:** cardiomyopeptidin

## Key facts

- **NCT ID:** NCT06155110
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06155110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06155110, "A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06155110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*